<DOC>
	<DOCNO>NCT02331875</DOCNO>
	<brief_summary>The primary objective open label Phase Ib/II trial evaluate clinical pharmacological activity IPH2201 single-agent treatment-naïve pre-operative patient operable Squamous Cell Carcinoma Oral Cavity . 43 patient plan enrol . The first 6 patient receive IPH2201 dose 4 mg/kg q2w x 4 . Subsequent patient treat dose 10 mg/kg q2w x 4 . Standard loco-regional treatment surgery follow adjuvant therapy initiate last administration IPH2201 .</brief_summary>
	<brief_title>Efficacy Study Pre-operative IPH2201 Patients With Squamous Cell Carcinoma Oral Cavity</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Squamous Cell</mesh_term>
	<criteria>Inclusion criterion : Histologically confirm , primary , previously untreated , resectable squamous cell carcinoma oral cavity consider clinically radiologically intermediate high risk , classify II ( large ( ≥ 3 cm ≤ 4cm ) cT2cN0cM0 tumor cT2cN0cM0 tumor invade neighboring structure ) III IVa accord American Joint Committee Cancer Adequate liver renal function Exclusion criterion : Other malignancy Abnormal cardiac status Autoimmune disease Serious concurrent uncontrolled medical disorder Systemic treatment corticosteroid immunosuppressive agent within 30 day prior IPH2201 first administration .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>